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USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE 
WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA: A 
GENERAL POPULATION STUDY
Jo C
Hallym University, Chuncheon, South Korea
OBJECTIVES: This study, using DCE method, ﬁ gures out the characteristics of the 
decision-making for cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for cancer treatment among the general population. METHODS: In the survey, 
the respondents are asked to choose more than one discrete choice option, resulting 
in multiple observations for each individual. For each pair-wise comparison of choice 
set, the respondent will make a choice among three alternatives; A, B, or opt out. 
Thus, the nested-logit model using full maximum likelihood allows us to empirically 
estimate multi-levels of dependent variables. For the robustness check of our empirical 
results, we try considering the nature of distribution of error terms in the utility func-
tion in several ways. The key assumption of logit models is the independence of 
irrelevant alternatives (IIA), which results from the assumption that other alternatives 
are independent. The validity of IIA assumption can be simply conducted by a 
Hausman-McFadden test. We also consider an alternative speciﬁ cation where error 
terms are independently, but not identically distributed. And ﬁ nally stand errors are 
calculated by using bootstrapping and compared to the previous results. RESULTS: 
In this DCE study, evidence of reliability was found at both input and output level. 
The estimates of MWTP between survival rate and monthly insurance premium and 
MTWP between total treatment costs and monthly insurance premium, by employing 
“Hybrid Conditional Fixed Effects Logit Model” to ﬁ gure out the existence of het-
erogeneity of any observed and unobserved components, are reﬂ ecting reasonable 
range of 817 KRW~1324KRW, and 23,690 KRW~38,139 KRW, respectively. CON-
CLUSIONS: Compared to female counterparts, male respondents have higher MWTP 
of monthly insurance premium for two related attributes. Besides, currently married 
respondents, with higher income, and higher educational attainments have more 
MWTP compared to their respective counterparts. 
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USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE MARGINAL 
WILLINGNESS TO PAY OF INSURANCE PREMIUM FOR LIVER CANCER 
TREATMENT IN KOREA
Jo C
Hallym University, Chuncheon, South Korea
OBJECTIVES: This study, using DCE method, ﬁ gures out the characteristics of the 
decision-making for liver cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for liver cancer treatment among the general population of 600 respondents in 
Korea. METHODS: In the survey, the respondents are asked to choose more than one 
discrete choice option, resulting in multiple observations for each individual. For each 
pair-wise comparison of choice set, the respondent will make a choice among three 
alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum likeli-
hood allows us to empirically estimate multi-levels of dependent variables. For the 
robustness check of our empirical results, we try considering the nature of distribution 
of error terms in the utility function in several ways. The survey questionnaire includes 
four attributes associated with liver cancer in Korea (incidence rates, survival rates, 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, and questions regarding risk averseness and subjective health evaluation. 
RESULTS: The estimates of MWTP between survival rate and monthly insurance 
premium and MTWP between total treatment costs for liver cancer and monthly 
insurance premium, by employing “Hybrid Conditional Fixed Effects Logit Model” 
to ﬁ gure out the existence of heterogeneity of any observed and unobserved compo-
nents, are reﬂ ecting ranges of 212 KRW~294 KRW and 3458 KRW~4777 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
married respondents, with higher education have more MWTP compared to their 
respective counterparts. One interesting point is that MWTP of high income group is 
lower than that of low income counterparts. This might be related to a lower alcohol 
consumption of high incomers who are less prone to liver cancer compared to low 
incomers. 
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PRIMARY HEPATOCELLULAR CARCINOMA PATIENTS’ REPEATED 
MEDICAL UTILIZATION AND EXPENDITURE FOR CONFIRMATION IN 
TAIWAN
Huang HH, Yang MC
National Taiwan University, Taipei, Taiwan
OBJECTIVES: Hepatocellular carcinoma is one of the most prevalent cancers in 
Taiwan. Since Taiwan’s National Health Insurance (NHI) system neither prohibit 
patients from choosing health-care facilities nor limit number of outpatient visits. 
Therefore, patients being diagnosed as having hepatocellular carcinoma may seek 
second or even third doctor to conﬁ rm their condition. Thus, the purpose of this study 
was to examine the effects of disease conﬁ rmation behavior on the medical utilization 
and expenditure for patients with hepatocellular carcinoma. METHODS: Data came 
the Longitudinal Health Insurance Database, which consisted of one million subjects 
of randomly selected samples from the entire NHI enrollee proﬁ le for 2005 to 2007. 
We selected patients with hepatocellular carcinoma by using the ICD-9-CM codes 
(155, 155.0, and 155.2). Medical utilization and expenditure of those patients within 
3 months after ﬁ rst being diagnosed as having hepatocellular carcinoma were extracted 
from the data set. RESULTS: There were 1282 new hepatocellular carcinoma patients 
in our sample and 258 patients (20.12%) were identiﬁ ed as having the behavior of 
repeated disease conﬁ rmation. Total repeated physician fee and repeated examination 
were NT$1,272,765 and NT$3,783,983, respectively. (US$1 = NT$31.86) The expen-
diture of examination in the ﬁ rst-repeated conﬁ rmation hospi Consultant in Medical 
Oncology, and Assistant Director for Clinical Research, Johns Hopkins Singapore 
International Medical Centre, Singapore tal was higher than that of ﬁ rst-diagnosis 
hospital (P < 0.01). The expenditure was highly related to having Charlson comorbid-
ity index score 2 or higher, received chemotherapy, embolization, surgical operation 
and conﬁ rmation in medical centers. CONCLUSIONS: Within 3 months after ﬁ rst 
time being diagnosed, 20.1% of hepatocellular carcinoma patients used repeated 
medical services to reconﬁ rm their disease. The expenditure of examination in the 
repeated visit was higher than that of the ﬁ rst time being diagnosed. Further investiga-
tion is needed to compare the long-term health status of patients with and without 
repeated conﬁ rmation behavior. 
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DRUG UTILIZATION AND PRICE TRENDS OF ORAL-CHEMOTHERAPY 
MEDICATIONS IN MEDICAID 1991–2008
Bian B, Guo JJ
University of Cincinnati College of Pharmacy, Cincinnati, OH, USA
OBJECTIVES: Numerous oral chemotherapies have been approved and widely used 
for the treatment of different cancers. The objective of this study is to examine drug 
utilization and price trends for oral chemotherapies in US Medicaid programs. 
METHODS: A total of 18 oral anti-cancer drugs were included in this research. A 
retrospective, descriptive time-series analysis was performed using the National Med-
icaid pharmacy claims database from 1991 to 2008. The quarterly prescription 
numbers and reimbursement amounts were calculated over time by summing data for 
individual drug products. The quarterly per-prescription reimbursement as a proxy 
for drug price was computed for the price of each oral chemotherapy drug. RESULTS: 
Total oral chemotherapy prescriptions increased from 176,000 in 1991 to 259,000 in 
2004. For individual drugs, the two top-sell drugs are Vesanoid® and Hydrea® in 
terms of prescription numbers. In 2006 the number of prescriptions dropped to 
164,535 due to the implementation of Medicare Part D, and increased to 188,689 in 
2008. Expenditure for oral chemotherapy drugs increased from $9.3 million in 1991 
to $112.3 million in 2005 then dropped to $100 million in 2008. Medicaid expendi-
ture for oral anti-cancer drugs reached to the peak in 2005 quarter 4, which was 
almost $29 million, then the expenditure dropped to $26.5 million in 2008 quarter 
4. Average oral chemotherapy drug payment per prescription also increased dramati-
cally from $1269 in 1991 to $14,297 in 2008. The price of newer oral chemotherapies 
is more expensive than older ones, and increased over time regardless other brands’ 
competitions. CONCLUSIONS: Increased utilization of oral chemotherapy drugs was 
paralleled with its increased expenditure, which may be due to their efﬁ cacy and safety 
proﬁ les. Increased price for oral chemotherapies may be due to biomarkers speciﬁ ca-
tions with limited patient pool or the shrink demand. 
PCN37
GAUGING THE ROLE OF HTA IN REIMBURSEMENT DECISION-MAKING 
ACROSS SEVEN MARKETS IN ASIA-PACIFIC
Dummett H, Shankland BDT
Double Helix Consulting, London, UK
OBJECTIVES: HTA is at different stages of development across the Asia-Paciﬁ c 
region, from the highly developed system in Australia at one extreme to China at the 
other, where the impetus to formalize HTA exists but guidelines and a dedicated 
agency do not. Understanding the weight of HTA as a driver of reimbursement 
decision-making both now and in the next 5 years is crucial for informing reimburse-
ment strategy. METHODS: A total of 20 HTA reviewers and academic health econo-
mists were interviewed across Australia, China, Korea, Malaysia, the Philippines, 
Taiwan and Thailand to understand the parameters of the HTA system, the impor-
tance of different stakeholders within the process and the decisions inﬂ uenced by HTA. 
RESULTS: HTA systems within Asia-Paciﬁ c exist at all stages of the HTA develop-
ment continuum. At one end sit two single national payer systems, Australia and 
Korea, in which demonstration of cost-effectiveness is a formal prerequisite for reim-
bursement. At the other extreme sit China and Malaysia in which no formal role for 
HTA yet exists, although the speed and direction of HTA development is likely to 
differ. In between sit the Philippines, Taiwan and Thailand win which the role of HTA 
is becoming more formalized, albeit largely as one among several criteria in decision-
making. CONCLUSIONS: HTA is developing rapidly within the markets we consid-
ered, rendering the submission of economic evidence mandatory in most markets. But 
a formal role for cost-effectiveness evaluation does not always translate into cost-
effectiveness being the basis for decision-making. Understanding the nuances of where 
HTA sits in the reimbursement system and how it is applied in practice in each market 
is essential for maximizing the possibility of favorable reimbursement. 
